

**COMPANY ANNOUNCEMENT**

3 September 2021

No. 18-2021 - Inside Information

**ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19**

**BIRKERØD, DENMARK** - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, this morning received notice of the following transactions by persons discharging managerial responsibilities according to MAR art. 19. The transaction notification form is listed below.

**Thomas Krarup comments on the sale of shares:** *"I have high confidence in the prospects for ViroGates. I remain a shareholder of ViroGates and only sold part of the shares I hold to finance subscription of shares based on my warrant program. I do not intend to sell additional shares in 2021."*



**Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them**

<b>1.</b>	<b>Details of the person discharging managerial responsibilities/person closely associated</b>													
a)	Name	Thomas Krarup												
<b>2.</b>	<b>Reason for the notification</b>													
a)	Position/status	VP Sales & Marketing												
b)	Initial notification/Amendment	Initial notification												
<b>3.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>													
a)	Name	ViroGates A/S												
b)	LEI	5493007TX8XS56RMZD94												
<b>4.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>													
a)	Description of the financial instrument, type of instrument  Identification code	Sales of shares  ISIN Code: DK0061030574												
b)	Nature of the transaction	Sales												
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>194</td> <td>500</td> </tr> <tr> <td>205</td> <td>2244</td> </tr> <tr> <td>206</td> <td>930</td> </tr> <tr> <td>206</td> <td>763</td> </tr> <tr> <td>209</td> <td>563</td> </tr> </tbody> </table>	Price(s)	Volume(s)	194	500	205	2244	206	930	206	763	209	563
Price(s)	Volume(s)													
194	500													
205	2244													
206	930													
206	763													
209	563													
d)	Aggregated information - Aggregated volume - Price	5000 shares DKK 1,020,903												
e)	Date of the transaction	Aug 20-30, 2021												
f)	Place of the transaction	First North Growth market Denmark (DSME)												

This announcement is also available on the [company's website](#).

**For further information, please contact:**

ViroGates A/S:

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: [jk@virogates.com](mailto:jk@virogates.com)

*Certified Advisor:*

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: [per.lonn@vhcorp.se](mailto:per.lonn@vhcorp.se)

**About ViroGates**

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000. Headquartered in Denmark, ViroGates' sales force covers the Nordics, Spain, and France, while distributors serve other markets. ViroGates' shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit [www.virogates.com](http://www.virogates.com).